Leaflet KRAZATI 200mg film-coated tablets
Indicated for: non-small cell lung cancer
Route of administration: oral
Substance: adagrasib (antineoplastic agent)
ATC: L01XX77 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Adagrasib is a medication used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. It is a specific inhibitor of the KRAS G12C mutation, which plays a key role in cancer cell growth and survival.
The medication is taken orally, usually once or twice daily, as directed by a doctor. Adagrasib has shown efficacy in reducing tumor size and slowing disease progression in patients with this specific mutation.
Common side effects include nausea, diarrhea, fatigue, and elevated levels of certain liver enzymes. In rare cases, it may cause severe liver toxicity or other serious adverse reactions.
Patients taking adagrasib should be regularly monitored for liver function and report any side effects or unusual symptoms to their doctor.
General data about KRAZATI 200mg
- Substance: adagrasib
- Date of latest medicines list: 01-06-2026
- Product code: W71715001
- Concentration: 200mg
- Pharmaceutical form: film-coated tablets
- Quantity: 180
- Product type: Generic medicine
- Price: 59750.56 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.